Molecular antigen arrays

Details Molecular antigen arrays Molecular antigen arrays

2006-11-20

2009-02-24

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S193100, C424S209100, C424S210100, C424S185100, C435S235100, C435S069300

Reexamination Certificate

active

07494656

ABSTRACT:
The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.

REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5928647 (1999-07-01), Rock
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6380364 (2002-04-01), Mueller et al.
patent: 6932971 (2005-08-01), Bachmann et al.
patent: 7094409 (2006-08-01), Bachmann et al.
patent: 7115266 (2006-10-01), Bachmann
patent: 7128911 (2006-10-01), Bachmann et al.
patent: 7138252 (2006-11-01), Bachmann et al.
patent: 7279165 (2007-10-01), Bachmann et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0157479 (2003-08-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 0 259 149 (1993-12-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 425 082 (1995-04-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/50461 (2000-08-01), None
patent: WO 00/59928 (2000-10-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 02/056905 (2002-07-01), None
patent: WO 03/024481 (2003-03-01), None
Abraham, J.M., et al., “An invertible element of DNA controls phase variation of type 1 fimbriae ofEscherichia coli,” Proc. Natl. Acad. Sci. USA 82:5724-5727, National Academy Press (1985).
Abraham, S.N., et al., “Glycerol-Induced Unraveling of the Tight Helical Conformation ofEscherichia coliType 1 Fimbriae,”J. Bacteriol. 174:5145-5148, American Society for Microbiology (1992).
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,”Virology 170:238-242, Academic Press, Inc. (1989).
Aguzzi, A., “Prion diseases, blood and the immune system: concerns and reality,”Haematologica 85:3-10, II Pensiero Scientifico Editore (Jan. 2000).
Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Cheomkine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,”J. Exp. Med. 190:1123-1134, The Rockefeller University Press (1999).
Ansel, K.M., et al., “A chemokine-driven positive feedback loop organizes lymphoid follicles,”Nature 406:309-314, Nature Publishing Group (Jul. 2000).
Antonysamy, M.A., et al., “Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the Functional Differentiation of Dendritic Cell Progenitors,”J. Immunol. 162:577-584, The American Association of Immunologists (1999).
Arenberg, D.A., et al., “The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model,”Cancer Immunol. Immunother. 49:587-592, Springer-Verlag (Jan. 2001).
Arnon, R., et al., “A mimotope peptide-based vaccine againstSchistosoma mansoni: synthesis and characterization,”Immunology 101:555-562, Blackwell Science, Ltd. (Dec. 2000).
Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17:553-558, Elsevier Science, Ltd. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation,”J. Exp. Med. 189:1025-1031, The Rockefeller University Press (1999).
Banerjee, R.R., and Lazar, M.A., “Dimerization of Resistin and Resistin-like Molecules Is Determined by a Single Cysteine,”J. Biol. Chem. 276:25970-25973, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2001).
Bard, F. et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nat. Med. 6:916-919, Nature Publishing Company (Aug. 2000).
Bass, S., and Yang, M., “Expressing cloned genes inEscherichia coli,” inProtein Function: A Practical Approach, 2nd ed., Creighton, T.E., ed., IRL Press, Oxford, Great Britain, pp. 29-55 (1997).
Bernhagen, J., et al., “Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF),”Biochemistry 33:14144-14155, American Chemical Society (1994).
Biaselle, C.J., and Millar, D.B., “Studies on Triton X-100 detergent micelles,”Biophys. Chem. 3:355-361, North-Holland Publishing Company (1975).
Bleul, C.C., et al., “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,”Nature 382:829-833, Nature Publishing Group (1996).
Blomfield, I.C., et al., “Type 1 Fimbriation andfimEMutants ofEscherichia coliK-12,”J. Bacteriol. 173:5298-5307, American Society for Microbiology (1991).
Blomfield, I.C., et al., “Integration host factor stimulates both FimB- and FimE-mediated site-specific DNA inversion that controls phase variation of type 1 fimbriae expression inEscherichia coli,” Mol. Microbiol. 23:705-717, Blackwell Science, Ltd. (1997).
Boder, E.T., and Wittrup, K.D., “Yeast Surface Display for Directed Evolution of Protein Expression, Affinity, and Stability,”Methods Enzymol. 328:430-444, Academic Press (Oct. 2000).
Bonci, A., et al., “Relatedness and Phylogeny Within the Family of Periplasmic Chaperones Involved in the Assembly of Pili or Capsule-Like Structures of Gram-Negative Bacteria,”J. Mol. Evol. 44:299-309, Springer-Verlag (1997).
Brandner, S., et al., “A crucial role for B cells in neuroinvasive scrapie,”Transfus. Clin. Biol. 6:17-23, Elsevier, Paris (1999).
Brinton, Jr., C.C., “The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria,”Trans. N.Y. Acad. Sci. 27:1003-1054, New York Academy of Sciences (1965).
Brown, K.D., et al., “A family of small inducible proteins

Affiliated with

Also associated with

Rating

Molecular antigen arrays does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecular antigen arrays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular antigen arrays will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4094553